Marine pharmacognosy Compounds from Marine Sources in Clinical Level Clinical Pipeline of Marine Pharmacology, July 2011. From http://marinepharmacology.midwestern.edu/clinPipeline.htm

| Clinical_Status | Compound_Name | Trademark | Marine_Organism_α | Chemical_Class | Molecular_Target | Clinical_Trials_β | Disease_Area |
|---|---|---|---|---|---|---|---|
| FDA-Approved | Cytarabine (Ara-C) | Cytosar-U ® | Sponge | Nucleoside | DNA Polymerase | >50/711 | Cancer |
| FDA-Approved | Vidarabine (Ara-A) | Vira-A ® | Sponge | Nucleoside | Viral DNA Polymerase | 0 | Antiviral |
| FDA-Approved | Ziconotide | Prialt ® | Cone Snail | Peptide | N-Type Ca 2+ Channel | 2/5 | Analgesic |
| FDA-Approved | Eribulin Mesylate (E7389) | Halaven ® | Sponge | Macrolide | s Microtubule | 19/27 | Cancer |
| FDA-Approved | Omega-3-Fatty Acid Ethyl Esters | Lovaza ® | Fish | Omega-3 Fatty Acids | Triglyceride -Synthesizing Enzymes | 45/94 | Hypertriglyceridemia |
| FDA-Approved | Trabectedin (ET-743) EU Approved only | Yondelis ® | Tunicate | Alkaloid | Minor Groove of DNA | 17/34 | Cancer |
| Phase III | Brentuximab Vedotin (SGN-35) | Adcetris ® | Mollusk | Antibody-Drug Conjugate (MM Auristatin E) | CD30 and Microtubules | 9/19 | Cancer |